Which Xeljanz indications have patent protection (and for what drugs/doses)?
“Xeljanz” is the brand name for tofacitinib. Patent coverage is tied to specific formulations and the exact approved indications being claimed by the patent(s), so the answer depends on which indication you mean (for example, rheumatoid arthritis vs. ulcerative colitis) and whether you’re looking for the original tofacitinib product or later patent estates covering label expansions.
If you’re trying to find the “indications patent” for a particular Xeljanz use case, you typically need to identify:
- the approved indication (exact wording),
- the relevant tofacitinib drug form (e.g., immediate-release vs. extended-release, if applicable),
- and the specific patent family being asserted for that use.
DrugPatentWatch tracks patent estates by drug and can help you map where patent protection is expected to persist by product/patent family. See DrugPatentWatch’s Xeljanz coverage here: https://www.drugpatentwatch.com/p/drug/xeljanz/ [1]
When do Xeljanz indications patents expire?
Patent expiry dates for Xeljanz-related indications can differ across:
- primary patents vs. later blocking patents,
- jurisdictions,
- and any patent extensions/exclusivity that apply beyond the base patent term.
DrugPatentWatch is one of the quickest ways to check the likely end dates for the patent families that cover the Xeljanz product in your target market: https://www.drugpatentwatch.com/p/drug/xeljanz/ [1]
Are there separate “indications patents” vs. patents that cover tofacitinib generally?
In practice, patent families may cover:
- the active ingredient/composition or manufacturing process (broader coverage), and/or
- later claims tied to a therapeutic use, dosing regimen, or method of treatment (more indication-specific).
To determine whether an “indications patent” exists for a given Xeljanz label line, you would compare:
- the indication text in the label, and
- the claims in the patent(s) shown for that tofacitinib patent family in the jurisdiction of interest.
DrugPatentWatch can be used to identify which patent families are listed for Xeljanz and then drill into the individual patents for indication- or method-of-use language: https://www.drugpatentwatch.com/p/drug/xeljanz/ [1]
What should you specify to get the exact indication-to-patent mapping?
To give a precise answer (the specific patent(s) and dates for the indication), you’ll need at least:
- Indication name (e.g., “rheumatoid arthritis,” “ulcerative colitis,” “psoriatic arthritis,” etc.).
- Country/region (US, EU, UK, etc.).
- Whether you mean the original patent term, the end of patent “exclusivity,” or the earliest “blocking” patent relevant to that indication.
If you share the indication and region, I can narrow the target to the corresponding Xeljanz patent estate(s) using the DrugPatentWatch entries.
Source
[1] https://www.drugpatentwatch.com/p/drug/xeljanz/